Task Force Report on Obstetric Antiphospholipid Syndrome
The obstetric criteria for antiphospholipid syndrome (APS) were first formalized in 1999 at the 10th International Congress on Antiphospholipid Antibodies (aPL). In 2010, the Organizing Committee for the upcoming 13th International Congress on aPL formed an Obstetric APS Task Force. The intent was to kindle discussion regarding obstetric APS prior to the meeting and then to engender participation among interested experts and attendees at a half-day Task Force meeting to be held the day before the official start of the Congress. The Task Force concluded that there is virtually no evidence from properly designed trials to guide clinicians with regard to prevention of fetal death, severe preeclampsia, or placental insufficiency attributed to APS. Also, no clear consensus was reached with regard to resolving discrepancies in existing trials of heparin treatment for recurrent early miscarriage attributed to APS. A majority of Task Force members were in agreement that studies in the field of APS must be carefully planned with regard to such critical elements as case and control matching and inclusion and exclusion criteria. Moreover, the ability to perform repeat testing and confirmatory testing in a central laboratory would be mandatory.
KeywordsTask Force Fetal Death Lupus Anticoagulant Severe Preeclampsia Postpartum Care
In addition to the authors, the Task Force Members for Obstetric APS were the following: Alijotas-Reig, Jaume, MD, PhD (Vall d’Hebron University Hospital, Universitat Autònoma, Barcelona, Spain), Alba, Paula, MD, PhD (Universidad Nacional de Cordoba, Cordoba, Argentina), Buyon, Jill, MD (Hospital for Joint Diseases, New York, NY), Cohen, Hannah, MD (University College London Hospitals, London, UK), Contreras, Juan A. MD, de Jesus, Guilherme MD (Universidade do Estado do Rio de Janeiro, Brazil), de Jesus, Nilson Ramires MD (Universidade do Estado do Rio de Janeiro, Brazil), Farran-Codina, Inma, MD, PhD, Grand, Beatriz, MD (University of Buenos Aires, Buenos Aires, Argentina), Greco, Thomas P., MD (Saint Mary’s Hospital, Waterbury, CT), Harraca, Monica G., MD, Kutteh, Billy, MD, PhD (University of Tennessee, Memphis, TN), Levy, Roger A., MD, PhD (Universidade do Estado do Rio de Janeiro, Brazil), Lockshin, Michael, MD (Hospital for Special Surgery, New York, NY), Makatsariya, Alexander, MD, PhD, Maria-Otero, Ana, MD, Michelon, Tatiana, MD, PhD, Pappalardo, Cecilia, MD (Halitus Medical Institute, Buenos Aires, Argentina), Parke, Ann, MD (University of Connecticut Health Center, Farmington, CT), Pierangeli, Silvia,PhD (University of Texas Medical Branch, Galveston, TX), Ruiz, Itziar Garcia, MD, Salmon, Jane, MD (Hospital for Special Surgery, New York, NY), Sarto, Adriana, MD (Halitus Medical Institute, Buenos Aires, Argentina), Silver, Robert, MD (University of Utah Health Sciences Center, Salt Lake City, UT), Zarzoso, Cristina, MD (Vall d’Hebron University Hospital, Universitat Autònoma, Barcelona, Spain).
- 7.Bruce IN, Clark-Soloninka CA, Spitzer KA, Gladman DD, Urowitz MB, Laskin CA. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol. 2000;27:2833–7.PubMedGoogle Scholar